Brief: Suven Life Sciences Approves Increasing Investment Limit In WOS In U.S. Suven Neurosciences
April 15 (Reuters) - Suven Life Sciences Ltd SUVP.NS :
* APPROVES INCREASING INVESTMENT LIMIT IN WOS IN U.S. SUVEN
NEUROSCIENCES FROM $25 MILLION UPTO $50 MILLION TO UNDERTAKE
CLINICAL TRIALS
Source text : https://reut.rs/2V4M24m
Further company coverage: SUVP.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences March-Quarter Consol Net Loss 439.4 Million Rupees